Floatz logo

xy0206

Advanced or Metastatic Solid Tumours

Shijiazhuang Yiling Pharmaceutical Co. LtdPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced or Metastatic Solid Tumours cohort.

Asset / SponsorPhaseRating
Apto-253
Aptose Biosciences Inc.
Phase 1CC
AK 127
Akesobio Australia Pty Ltd
Early Phase 1CC

Same molecule, other indications

xy0206 is also rated in:

acute myeloid leukemia, FLT3 internal tandem duplicationDormant
BB
Indicative ·
64 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →